05 jan: DSV, 642 - Storaktionærmeddelelse
06 jan: Indre værdi af SmallCap Danmark A/S er opgjort til 84,4 kr. pr. ..
06-01-2017 07:58:46

Knud Vindfeldt steps down from the Executive Board of Chr. Hansen Holding A/S

Relateret indhold
22 mar - 
Novo A/S øgede life-science-investeringer sidste år til..
16 feb - 
Nestlés vækst skuffer ledelsen og aktiemarkedet
15 feb - 
Aktier/tendens: Stigninger i vente - finansaktier og Ge..
Relateret debat
20 feb - 
Mange mange tak
20 feb - 
PURE, HBIO, ROKA, PLSE, PACB
20 feb - 
Hvilke andre firmaer arbejder med samme forretningsomr&..

Hoersholm, 2017-01-06 07:58 CET (GLOBE NEWSWIRE) --

 

Company announcement No. 01/2017

After more than 25 years with Chr. Hansen and 11 years in Executive Management, Knud Vindfeldt will step down from the Executive Board of Chr. Hansen Holding A/S on 28 February 2017.

Knud Vindfeldt joined Chr. Hansen in 1991 and was appointed member of the Executive Board of Chr. Hansen Holding A/S and head of the Cultures & Enzymes Division in 2005, and was further appointed COO and Deputy CEO in 2016. After February, Knud will continue to support Chr. Hansen in the role of advisor to the CEO for a period of six months.

Cees de Jong, CEO of Chr. Hansen, says: “Knud has been one of the key drivers behind the success of Chr. Hansen in the dairy market, and he has relentlessly pushed for continued improvements in our strategic, operational and financial performance. The results delivered by the Food Cultures & Enzymes Division (FC&E) speak for themselves; since 2005, both revenue and EBIT margin have more than doubled.

“With the transfer of the commercial responsibility for FC&E to Christoffer Lorenzen in April last year, the recent recruitment of Thomas Schäfer as Chief Scientific Officer and, today, with the promotion of Torsten Steenholt to Executive Vice President, Global Operations and member of the Corporate Leadership Team, we have ensured Knud’s succession. On behalf of the entire Chr. Hansen organization, I would like to thank Knud for his exceptional contribution to Chr. Hansen and wish him all the best for the future.”

Knud Vindfeldt says: “Chr. Hansen is a truly great company and it has been a fantastic journey, which I am proud to have been part of. The company is in better shape than ever, delivering solid results. With such strong successors in place, I feel confident that this is a natural time for me to step down. In the coming months, we will ensure a good handover.”

Following this change, the Executive Board will consist of CEO Cees de Jong and CFO Søren Westh Lonning. In addition, and as previously announced, Thomas Schäfer will join Chr. Hansen as CSO and member of the Executive Board in due course.

For further information, please contact:

Anders Mohr Christensen, Senior Director, Investor Relations

Tel.: +45 4574 7618

Camilla Lercke, Head of Media Relations

Tel.: +45 5339 2384

 

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2015/16 financial year was EUR 949 million. The company has more than 2,700 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen A/S. For further information, please visit www.chr-hansen.com.

 

Vedhæftet fil: No 01 2017 US.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Novo: EMA-udvalg anbefaler markedsføringstilladelse til Refixia - NY

24-03-2017 13:31:36
Udvalget for humanmedicinske lægemidler (CHMP) ved Det Europæiske Lægemiddelsagentur (EMA) har tildelt Novo Nordisks Refixia en positiv udtalelse og anbefaler en markedsføringstilladelse.Det skriver Novo Nordisk i en fondsbørsmeddelelse.CHMP anbefaler en markedsføringstilladelse til Refixia til unge og voksne med hæmofili B. Til grund for anbefalingen ligger resultater fra udviklingsprogrammet par..

Novo/Exane: Kursmålet skæres til 270 kr.

24-03-2017 10:17:22
Den franske storbank Exane BNP Paribas skærer kursmålet for aktien i Novo Nordisk til 270 kr. fra 295 kr. Anbefalingen er uændret "outperform", viser data fra Bloomberg.Novo-aktien falder fredag 0,4 pct., eller 1 kr., til 233,20 kr. Det dækker dog over en stigning, da aktien ikke længere handles inklusive retten til et udbytte på 4,60 kr./ritzau/FINANSJakob Dalskov +45 33 30 03 35 Ritzau Finans, E..

Aktier/tendens: Mulighed for mere gas til Mærsk i ventet rødt C20

24-03-2017 08:31:54
Det danske aktiemarked kan fredag blive præget af små udsving med en lille overvægt af negative fortegn.A.P. Møller-Mærsks B-aktie var uændret efter torsdagens handel og blev handlet til 11.500 kr. Aktien kan dog gå fra grå til grøn fredag, da der er potentielt gode nyheder til det danske konglomerat.Efter en Nordsø-aftale, der kan redde det ellers lukningstruede Tyra-felt, skriver Jyllands-Posten..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo/Exane: Kursmålet skæres til 270 kr.
2
Novo: EMA-udvalg anbefaler markedsføringstilladelse til Refixia - NY
3
Aktier/tendens: Mulighed for mere gas til Mærsk i ventet rødt C20
4
Novo er et skridt nærmere vigtigt markedsføringsargument for Tresiba
5
DSV/Goldman: Anbefaling sænkes efter kursræs

Relaterede aktiekurser

Chr Hansen Holding A/S 443,90 1,1% Stigning i aktiekurs
CHR Hansen Hldg DKK10 59,10 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. marts 2017 22:49:25
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB3 - 2017-03-24 22:49:25 - 2017-03-24 22:49:25 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x